Susana Miranda

14.9k total citations
36 papers, 1.3k citations indexed

About

Susana Miranda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Susana Miranda has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Susana Miranda's work include Prostate Cancer Treatment and Research (19 papers), Cancer Genomics and Diagnostics (10 papers) and PARP inhibition in cancer therapy (6 papers). Susana Miranda is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Cancer Genomics and Diagnostics (10 papers) and PARP inhibition in cancer therapy (6 papers). Susana Miranda collaborates with scholars based in United Kingdom, Spain and United States. Susana Miranda's co-authors include Johann S. de Bono, Gerhardt Attard, David Lorente, Mateus Crespo, Aránzazu Mendía, Elena Cerrada, Mariano Laguna, Roberta Ferraldeschi, Fabian Mohr and Diletta Bianchini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Susana Miranda

33 papers receiving 1.3k citations

Peers

Susana Miranda
Gareth Hughes United Kingdom
Nathalie Auger France
Sylvia S. W. Ng Canada
Maria Giovanna Dal Bello Italy
Dylan Conklin United States
Chunrong Li United States
Todd R. Palmby United States
Haitian Quan China
Sandra Heskamp Netherlands
Jean Cui United States
Gareth Hughes United Kingdom
Susana Miranda
Citations per year, relative to Susana Miranda Susana Miranda (= 1×) peers Gareth Hughes

Countries citing papers authored by Susana Miranda

Since Specialization
Citations

This map shows the geographic impact of Susana Miranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susana Miranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susana Miranda more than expected).

Fields of papers citing papers by Susana Miranda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susana Miranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susana Miranda. The network helps show where Susana Miranda may publish in the future.

Co-authorship network of co-authors of Susana Miranda

This figure shows the co-authorship network connecting the top 25 collaborators of Susana Miranda. A scholar is included among the top collaborators of Susana Miranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susana Miranda. Susana Miranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Almeida, Gilberto S., Philippa King, Albert Hallsworth, et al.. (2025). Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging. Neoplasia. 65. 101170–101170.
2.
Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480. 1 indexed citations
3.
Neeb, Antje, Ines Figueiredo, Bora Gürel, et al.. (2023). Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer. Laboratory Investigation. 103(11). 100245–100245.
4.
Carreira, Suzanne, Susana Miranda, Ines Figueiredo, et al.. (2023). Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. European Urology Open Science. 52. 72–78. 5 indexed citations
5.
Sheehan, Beshara, Antje Neeb, Lorenzo Buroni, et al.. (2022). Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clinical Cancer Research. 28(14). 3104–3115. 22 indexed citations
6.
Biondo, Andrea, Abhijit Pal, Ruth Riisnaes, et al.. (2021). Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience. Cancer Treatment and Research Communications. 27. 100309–100309. 2 indexed citations
7.
Rodrigues, Daniel Nava, Nicola Casiraghi, Alessandro Romanel, et al.. (2018). RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(2). 687–697. 44 indexed citations
8.
Rescigno, Pasquale, David Lorente, David Dolling, et al.. (2018). Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. European Urology Oncology. 1(1). 71–77. 27 indexed citations
9.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2018). Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology. 29(7). 1554–1560. 72 indexed citations
10.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2016). Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. 70(6). 985–992. 113 indexed citations
11.
Lorente, David, Aurelius Omlin, Zafeiris Zafeiriou, et al.. (2016). Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clinical Genitourinary Cancer. 14(6). 485–493. 27 indexed citations
12.
Crespo, Mateus, Guus van Dalum, Roberta Ferraldeschi, et al.. (2015). Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British Journal of Cancer. 112(7). 1166–1174. 53 indexed citations
13.
Box, Gary, Nina Tunariu, Mateus Crespo, et al.. (2014). Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. JNCI Journal of the National Cancer Institute. 106(4). dju033–dju033. 51 indexed citations
14.
Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586. 72 indexed citations
15.
Powers, Marissa, Melanie Valenti, Susana Miranda, et al.. (2013). Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget. 4(11). 1963–1975. 29 indexed citations
16.
Carden, Craig P., Adam Stewart, Emma Kipps, et al.. (2012). The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics. 11(7). 1609–1617. 81 indexed citations
17.
Reid, Alison, Gerhardt Attard, Daniel Brewer, et al.. (2012). Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Modern Pathology. 25(6). 902–910. 35 indexed citations
18.
Perkins, Géraldine, Timothy A. Yap, Lorna Pope, et al.. (2012). Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. PLoS ONE. 7(11). e47020–e47020. 126 indexed citations
19.
20.
Miranda, Susana, et al.. (1997). Papanicolaou smear, colposcopy, vaginoscopy and vulvoscopy in HIV positive and negative women. Acta Obstetricia Et Gynecologica Scandinavica. 76. 90. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gareth Hughes Breakdown of academic impact, for papers by Nathalie Auger Breakdown of academic impact, for papers by Sylvia S. W. Ng Breakdown of academic impact, for papers by Maria Giovanna Dal Bello Breakdown of academic impact, for papers by Dylan Conklin Breakdown of academic impact, for papers by Chunrong Li Breakdown of academic impact, for papers by Todd R. Palmby Breakdown of academic impact, for papers by Haitian Quan Breakdown of academic impact, for papers by Sandra Heskamp Breakdown of academic impact, for papers by Jean Cui
Rankless by CCL
2026